Press Release    Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company’s Executive Committee. This appointment is part of EUROAPI’s ongoing FOCUS-27 transformation plan and reinforces its position as a ...

JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025.Three (3) Months of 2025 Financial Summary Revenues for the t ...

Core Insights - BioHarvest Sciences Inc. has secured a new contract for developing a plant-based fragrance compound, targeting the multi-billion-dollar fragrance and scents market [1][3] - The contract will utilize the company's proprietary Botanical Synthesis technology and advanced AI-assisted research capabilities to identify specific plant species for efficient production [2][4] - The agreement includes milestone-based payments and a non-disclosure agreement for the initial stage of the project [3] Company Overview - BioHarvest is a leader in Botanical Synthesis, leveraging patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5][6] - The CEO emphasized the contract's potential to expand the company's reach into the high-value fragrance space while contributing to the conservation of threatened plant species [4]

Core Insights - BioHarvest Sciences Inc. has transitioned to stage two of its partnership with a pharmaceutical company, marking a significant milestone in the development of plant-derived biological materials for approved drugs [1][4] - The transition involves cultivating specific plant cells in liquid media within small-scale bioreactors, which is a crucial step towards commercial scalability [2][5] Group 1 - Stage one focused on identifying and working with specific plant cells to produce targeted phyto-medicinal compounds using solid media in petri dishes [4][5] - Stage two represents a shift to liquid media cultivation in small-scale bioreactors, which is essential for scaling up production [5][6] - Successful completion of stage two will lead to stage three, where cells will be grown in large-scale industrial bioreactors, with current operations already utilizing bioreactors of 1,200 liters and above [6] Group 2 - The company's mission is to discover, develop, manufacture, and democratize life-changing plant compounds that promote health and wellness while preserving the planet [7] - The transition from stage one to stage two validates the company's work and demonstrates the effectiveness of its botanical synthesis platform, which has been developed over 17 years [8]

Core Insights - WuXi Biologics has received the 2025 CDMO Leadership Awards in the "Biologics - Global" category, marking its eighth consecutive year of recognition for excellence in various areas [1][2][3] Company Achievements - The company has demonstrated a commitment to advancing integrated technology platforms, significantly shortening the development time for monoclonal antibody projects to 9 months, with a recent autoimmune disease project completed in just 6 months [2] - WuXi Biologics has scaled its manufacturing capacity from 4,000 to 16,000 liters using single-use technology (SUT), achieving a 99% success rate from 2022 to 2024 [2] - The company has maintained a 100% success rate in pre-approval inspections (PAI) and has passed over 40 inspections by global regulatory agencies, including 22 by the FDA and EMA [2] Leadership and Recognition - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the importance of the award as a reflection of the trust from global partners and the dedication of the team [3] - The CDMO Leadership Awards evaluated 210 CDMOs based on third-party research, recognizing top performers in four categories across three service regions [3] Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [4] - The company employs over 12,000 skilled employees across multiple countries, supporting 817 integrated client projects, including 21 in commercial manufacturing [5] Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone of long-term growth, driving green technology innovations and achieving excellence in Environment, Social, and Governance (ESG) practices [6]

Core Insights - Scinai Bioservices, a CDMO unit launched by Scinai in 2024, operates from a facility in Jerusalem, Israel, featuring 1,850 square meters of clean rooms and laboratories compliant with cGMP standards [2][3] - The CDMO unit has engaged in drug development projects for various biotech companies, including upstream and downstream process development, scale-up, and drug manufacturing for clinical trials [3] - Scinai's U.S. subsidiary aims to support early-stage biotech companies by providing essential CDMO services that are currently in short supply, allowing startups to utilize government grant funding [4] Company Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with two main business units: one focused on developing biological therapeutic products for inflammation and immunology, and the other providing CDMO services to early-stage biotech companies [5] - The company is actively seeking potential pharma partners interested in co-developing or in-licensing its innovative NanoAbs targeting diseases with significant unmet medical needs [7] Business Development - Scinai has partnered with Ayana Pharma to offer liposomal encapsulated drug development services, enhancing its capabilities in the CDMO sector [3] - The company is positioned to attract institutional and private investors by showcasing its value proposition in the biopharmaceutical market [7]

Core Insights - Humanetics Corporation is developing BIO 300, a novel radioprotective agent aimed at preventing acute radiation syndrome, with support from the Department of Defense [1][3] - Lifecore Biomedical has been selected to provide contract development and manufacturing services for BIO 300, including technology transfer and analytical method activities [1][2] - The collaboration highlights the innovation within Minnesota's life sciences sector and aims to provide critical protection against radiation exposure for military personnel and civilians [2] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products, with over 40 years of experience [4] - Humanetics Corporation focuses on the discovery and development of proprietary drugs for urgent medical needs, particularly in radiation countermeasures and oncology [5] Financial Support - The development of BIO 300 is supported by a grant of $5,132,520 from the Department of Defense through the Peer Reviewed Medical Research Program [3]

Core Insights - Avid Bioservices, Inc. has launched a new corporate website aimed at enhancing visitor experience for current and prospective customers [1][2][3] Company Overview - Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on biologics, providing a comprehensive range of services including CGMP clinical and commercial manufacturing [4] - The company has over 30 years of experience in producing biologics and offers services such as process development, bulk packaging, and regulatory submissions support [4] Website Features - The new website features an improved user experience with user-friendly navigation, enhanced accessibility, video interaction, and educational resources [2][3] - The tagline "Discover the Avid effect.™" is used to highlight the company's differentiation and position as a trusted biologics CDMO [2] Leadership Perspective - The CEO of Avid emphasized the importance of aligning the online presence with the company's commitment to exceptional quality service and customer satisfaction [3]

Core Points - Avid Bioservices, Inc. announced a Fundamental Change and a Make-Whole Fundamental Change occurred on February 5, 2025, due to the closing of a merger transaction [1][2][5] - Holders of the 7.00% Convertible Senior Notes due 2029 have the right to require the company to repurchase their notes at 100% of the principal amount plus accrued interest on March 12, 2025 [2][4] - The company will increase the Conversion Rate for notes surrendered for conversion during the Make-Whole Fundamental Change Conversion Period, which ends on March 10, 2025 [5][10] Company Overview - Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on biologics, providing a range of services including process development and CGMP manufacturing for biotechnology and pharmaceutical companies [13]

Acquisition Overview - GHO Capital Partners and Ampersand Capital Partners have successfully closed the acquisition of Avid Bioservices, a dedicated biologics Contract Development and Manufacturing Organisation (CDMO), in an all-cash transaction valued at approximately $1.1 billion [1][4][7] - Avid's stockholders will receive $12.50 per share in cash, and the company's common stock will be delisted from Nasdaq [4][7] Company Growth and Capabilities - Avid has experienced significant growth, offering full lifecycle capabilities from concept to commercial supply, with substantial investments in state-of-the-art facilities and expertise in bioprocess optimization, analytical testing, and regulatory compliance [2][9] - The company provides a comprehensive range of services including CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support, leveraging over 30 years of experience in producing biologics [9] Strategic Focus of GHO and Ampersand - GHO has considerable expertise in the CDMO sector, focusing on expanding technological capabilities, driving acquisitions, and supporting transatlantic expansion across the CDMO value chain [3][10] - Ampersand Capital Partners, with $3 billion in assets under management, is dedicated to growth-oriented investments in the healthcare sector, leveraging a blend of private equity and operating experience to build value [10] Leadership Insights - GHO's Managing Partners expressed excitement about the acquisition, highlighting Avid's strong foundation for future growth and the potential to unlock the business's full potential [4] - Avid's President and CEO noted that the new ownership will provide access to resources that will accelerate growth and enhance capabilities [4]